Cannabis Science Releases Second Cannabis-Extract-Based Formulation Available Now at Marisol Therapeutics, 922 Kimble Drive, ...
November 23 2011 - 2:19PM
Business Wire
Cannabis Science, Inc. (OTCBB; CBIS), a pioneering US biotech
company developing pharmaceutical cannabis products, is pleased to
announce the successful release of the second Cannabis Science
brand formulation. The Company has been receiving a constant flow
of inquires via its website, emails, and telephone calls for
cannabis-extract based medicines. For example, cancer patients
seeking extract-based formulations for topical or internal use have
frequently contacted Cannabis Science. Manufacturing and packaging
has been completed and is now available through Marisol
Therapeutics for patient usage.
PHONE: 719-547-4000
ADDRESS: 922 Kimble Drive Pueblo West, CO 81007
EMAIL: INFO@MARISOLMED.COM
In light of the accumulating anecdotal reports of the successful
cancer treatments with cannabis extracts, the Company will continue
to keep patients updated on current peer-reviewed scientific
literature supporting the historical and modern use of cannabis to
treat "tumors”. Unlike conventional treatment, cannabis medicines
have an outstanding safety profile allowing patients in states with
medical marijuana laws to safely make informed decisions to legally
self-administration of various cannabis-based preparations.
The second Cannabis Science Brand extract-based formulation is
comprised of high quality extract packaged in oral dispensing
syringes for patient self-administration for treatment. This is a
critical milestone for the Company in bringing its second
formulation to market. Other formulations will be made available
soon to medical marijuana patients in Colorado and around the world
through the Company’s vetted dispensaries. The Company’s intent is
to work with specially appointed legal providers and laboratories
to expand the availability of its formulations across the United
States and the world where legally available.
Dr. Melamede stated, “Cannabis Science is very proud with the
release of this second cannabis extract based formulation.
Discussions that are going on around the world in the scientific
and medical communities as well as conversations with patients all
point to a market need for these types of cannabis formulations. We
look forward to future releases of more cannabis extract based
formulations over the next year as we expand into California, and
other States around the United States and the globe where medical
cannabis is legal and can be accessed by the patients that need it
most.”
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing works such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc.
does not undertake any duty nor does it intend to update the
results of these forward-looking statements.